贝伐单抗（阿瓦斯汀®）用于持续性、复发性或转移性宫颈癌：可延长生存期数月，但毒性很大。
bevacizumab (Avastin°) in persistent, recurrent or metastatic cervical cancer: Prolongs survival by a few months, but highly toxic.
出版信息
Prescrire Int. 2016 Oct;25(175):233.
PMID:30645824
Abstract
In an unblinded trial in 452 patients with persistent, recurrent or metastatic cervical cancer, adding bevacizumab to other cytotoxic drugs prolonged median survival by 4 months, but adverse effects were often severe and sometimes fatal. Tailored symptomatic care is also a valid option.
摘要
在一项针对452例持续性、复发性或转移性宫颈癌患者的非盲法试验中，在其他细胞毒性药物基础上加用贝伐单抗可使中位生存期延长4个月，但不良反应往往很严重，有时甚至致命。针对性的对症治疗也是一种有效的选择。
Zotero 插件